- Home
- BCYC vs NAMS Comparison
BCYC vs NAMS Comparison
Compare BCYC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- NAMS
- Stock Information
- Founded
- BCYC 2009
- NAMS 2019
- Country
- BCYC United Kingdom
- NAMS Netherlands
- Employees
- BCYC N/A
- NAMS N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BCYC Health Care
- NAMS Health Care
- Exchange
- BCYC Nasdaq
- NAMS Nasdaq
- Market Cap
- BCYC 1.7B
- NAMS 1.7B
- IPO Year
- BCYC 2019
- NAMS N/A
- Fundamental
- Price
- BCYC $15.59
- NAMS $26.50
- Analyst Decision
- BCYC Buy
- NAMS Strong Buy
- Analyst Count
- BCYC 9
- NAMS 6
- Target Price
- BCYC $36.00
- NAMS $36.20
- AVG Volume (30 Days)
- BCYC 880.7K
- NAMS 1.4M
- Earning Date
- BCYC 10-31-2024
- NAMS 02-06-2025
- Dividend Yield
- BCYC N/A
- NAMS N/A
- EPS Growth
- BCYC N/A
- NAMS N/A
- EPS
- BCYC N/A
- NAMS N/A
- Revenue
- BCYC $36,898,000.00
- NAMS $33,594,000.00
- Revenue This Year
- BCYC $40.52
- NAMS $129.49
- Revenue Next Year
- BCYC N/A
- NAMS N/A
- P/E Ratio
- BCYC N/A
- NAMS N/A
- Revenue Growth
- BCYC 48.60
- NAMS 78.77
- 52 Week Low
- BCYC $12.17
- NAMS $10.29
- 52 Week High
- BCYC $28.67
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- BCYC 37.83
- NAMS 68.38
- Support Level
- BCYC $12.17
- NAMS $24.40
- Resistance Level
- BCYC $21.50
- NAMS $27.29
- Average True Range (ATR)
- BCYC 1.36
- NAMS 1.57
- MACD
- BCYC -0.36
- NAMS 0.63
- Stochastic Oscillator
- BCYC 49.67
- NAMS 94.52
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.